buffer [FBB; HBSS (0.4 g/L KCl, 0.06 g/L K 2 HPO 4 , 8 g/L NaCl, 0.048 g/L Na 2 HPO 4 , 1 g/L D-glucose (pH7.4), 2% BSA, 0.05% azide] at 4°C for 1 h with gentle agitation. FBB (300 μl) containing 0.7 μl PDGFR-(APA5) was added to 10 6 cells, and incubated for 45 min with gentle agitation at 4°C. After two washes with 1 ml FBB, 250 μl FBB containing Alexa Fluor 647 goat-anti-rat IgG (H+L) was added. After 45 min with gentle agitation at 4°C, cells were washed twice with 1 ml FBB and resuspended in 300 μl FBB. Flow cytometry was performed on a FACSScan (Becton Dickinson) and data analyzed using Cell Quest software (Becton Dickinson).
Fluorescence data were collected using logarithmic amplification on 10,000 light scatter-gated cells (cell counts). Negative controls were cells incubated with secondary antibody alone.
Whole mount analysis. The fourth abdominal mammary gland was surgically dissected, stretched onto a glass slide and fixed in 10% formalin overnight at room temperature. After washing in 70% ethanol for 15 min, the slides were rinsed with gently running tap water and distiled water for 5 min each, and stained overnight in an alum carmine solution (0.2% w/v carmine and 0.5% w/v aluminium potassium phosphate; Sigma). Whole mounts were dehydrated through a graded series of ethanol solutions, de-lipidified in toluene, mounted in Permount™ (Thermo Fisher Scientific) and photographed. Lesion areas in the images were measured using ImageJ software (National Institutes of Health).
Cell proliferation assay. For CHO/PyMT cells grown in suspension, cultures were initiated in triplicate at 2 10 4 cells per ml containing 6, 8 or 10 μM MEK1/2 inhibitor U0126 (diluted from 10 mM stock) in 10 ml + -MEM with 7.5% FBS; DMSO at the same final concenration was added to controls. An aliquot was counted every 24 h for 5 days and the inhibitor was replenished on the third day. For tumor epithelial cells grown in monolayer, cultures were initiated in triplicate in a 6-well plate at 2 10 4 cells per well containing 0, 5 or 10 μM MEK1/2 inhibitor (U0126) in 3 ml + -MEM with 7.5% heat-inactivated FBS, 3 μl DMSO was added to controls. Cells were counted from triplicate wells every 24 h for 5 days and the inhibitor was replenished on the third day.
Growth factor signaling assay. Cells 85-90% confluent in 60 mm dishes were serum-starved for 24 h. For MEK1/2 inhibitor treatments after starvation, 10 μM U0126 or DMSO equivalent in 1.5 ml + -MEM was added for 2 h at 37°C, cells were washed twice with + -MEM and treated with 50 ng/ml human PDGF-AB or EGF at 50 ng/ml at 37°C at the indicated time points. After stimulation, cells were collected and Western blot analyses were performed as described in the manuscript Methods.
Western and lectin blot analysis. TEC cells were subjected to western blot analysis with anti-PyMT Ab and anti--actin and lectin blot analysis with biotinylated-E-PHA as described in the manuscript Methods.
Supplemental Results
Flow cytometry using anti-PDGFR-extracellular domain showed that the different CHO/PyMT cell lines expressed similar cell surface levels of PDGFR- (Fig.   S1 ). Therefore differences observed in signaling induced by PDGF were not due to differences in PDGFR cell surface levels.
In Fig. S2 the effects of the MEK1/2 inhibitor U0126 on signaling and cell proliferation were investigated. U0126 caused not only reduced Erk1/2 phosphorylation but also reduced proliferation of CHO and LEC10B cells, thereby functionally correlating MAP kinase signaling to cell proliferation. The ~40%-50% decrease in signaling ( Fig. S2B ) caused by 10 μM U0126 resulted in a significant decrease in cell growth (Fig. S2A ). LEC10B/PyMT cells were more inhibited by UO126 than CHO cells at all concentrations. Fig. S3 shows that primary tumor lesions at 5 weeks were generally larger in Mgat3 -/-/PyMT mammary glands than in littermate controls. Table S1 . All TEC lines expressed PyMT RNA (Fig. S4A ) and protein and were keratin 8-positive and vimentin-negative based on western blot analyses (not shown). Mgat3 +/-/PyMT lines expressed Mgat3 RNA (Fig. S4A ) and possessed glycoproteins that bound E-PHA much better than those lacking Mgat3 (Fig. S4B) . Signaling stimulated by 50 ng/ml EGF or 10% serum (Fig. S4C ) was enhanced in both the Mgat3 -/-/PyMT lines.
In Fig. S5 , TECs derived from mammary tumors were compared for EGFstimulated signaling and cell proliferation in the presence and absence of the inhibitor UO126. The Mgat3 +/-/PyMT tumor cells exhibited less signaling in response to EGF than Mgat3 -/-/PyMT tumor cells and signaling in both lines was inhibited by UO126 ( Fig. S5A ). Fig. S5B shows that Mgat3 -/-/PyMT tumor cells proliferated faster than Mgat3 +/-/PyMT tumor cells, and that proliferation was inhibited by U0126.
Interestingly, mammary TECs were more sensitive to the MEK1/2 inhibitor than CHO cell for inhibition of both signaling and cell proliferation. 
Supplemental Figure Legends

